874570-85-1Relevant articles and documents
Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists
Mercer, Stephen E.,Chaturvedula, Prasad V.,Conway, Charles M.,Cook, Deborah A.,Davis, Carl D.,Pin, Sokhom S.,Macci, Robert,Schartman, Richard,Signor, Laura J.,Widmann, Kimberly A.,Whiterock, Valerie J.,Chen, Ping,Xu, Cen,Herbst, John J.,Kostich, Walter A.,Thalody, George,Macor, John E.,Dubowchik, Gene M.
, (2020/12/17)
Calcitonin gene-related peptide (CGRP) receptor antagonists have been shown clinically to be effective treatments for migraine. Zavegepant (BHV-3500, BMS-742413) is a high affinity antagonist of the CGRP receptor (hCGRP Ki = 0.023 nM) that has
CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS
-
Page/Page column 108, (2008/06/13)
The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
